Impact of high-throughput screening in biomedical research
The DOI matches its Crossref record; 65 of the 65 references it cites were found in a registry or an index.
Abstract
High-throughput screening (HTS) has been postulated in several quarters to be a contributory factor to the decline in productivity in the pharmaceutical industry. Moreover, it has been blamed for stifling the creativity that drug discovery demands. In this article, we aim to dispel these myths and present the case for the use of HTS as part of a proven scientific tool kit, the wider use of which is essential for the discovery of new chemotypes.
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“Cell-based phenotypic screening of chemical libraries represents a powerful tool to identify new potential drugs48.”
From Identification and characterization of Cardiac Glycosides as senolytic compounds (2019) · cites this paper as [48]
Citations
Cites
Zhang, J.-H., Chung, T. D. Y., & Oldenburg, K. R. (1999) · SLAS Discovery · doi:10.1177/108705719900400206 · Cited by 6,847 · cited 1×
“HTS laboratories have pioneered and implemented rigorous quality assurance methods, such as Z′ trend monitoring”
MethodCan the pharmaceutical industry reduce attrition rates?
Kola, I., & Landis, J. (2004) · Nature Reviews Drug Discovery · doi:10.1038/nrd1470 · Cited by 4,167
How to improve R&D productivity: the pharmaceutical industry's grand challenge
Paul, S. M., Mytelka, D. S., Dunwiddie, C. T., Persinger, C. C., Munos, B. H., Lindborg, S. R., & Schacht, A. L. (2010) · Nature Reviews Drug Discovery · doi:10.1038/nrd3078 · Cited by 3,566 · cited 1×
“These efforts typically take 2–3 years in most drug discovery companie”
BackgroundDrug repositioning: identifying and developing new uses for existing drugs
Ashburn, T. T., & Thor, K. B. (2004) · Nature Reviews Drug Discovery · doi:10.1038/nrd1468 · Cited by 3,237 · cited 1×
“There have been numerous analyses of pharmaceutical industry productivity, and several of these have blamed high-throughput screening (HTS) as a factor undermining the creativity that has sustained the industry over the past centur”
BackgroundDiscovery and development of sorafenib: a multikinase inhibitor for treating cancer
Wilhelm, S., Carter, C., Lynch, M., Lowinger, T., Dumas, J., Smith, R. A., Schwartz, B., Simantov, R., & Kelley, S. (2006) · Nature Reviews Drug Discovery · doi:10.1038/nrd2130 · Cited by 1,829
Lessons from 60 years of pharmaceutical innovation
Munos, B. (2009) · Nature Reviews Drug Discovery · doi:10.1038/nrd2961 · Cited by 1,207
Dorr, P., Westby, M., Dobbs, S., Griffin, P., Irvine, B., Macartney, M., Mori, J., Rickett, G., Smith-Burchnell, C., Napier, C., et al. (2005) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.49.11.4721-4732.2005 · Cited by 1,152
Hit and lead generation: beyond high-throughput screening
Bleicher, K. H., Böhm, H.-J., Müller, K., & Alanine, A. I. (2003) · Nature Reviews Drug Discovery · doi:10.1038/nrd1086 · Cited by 1,056
Chemical genetics strategy identifies an HCV NS5A inhibitor with a potent clinical effect
Gao, M., Nettles, R. E., Belema, M., Snyder, L. B., Nguyen, V. N., Fridell, R. A., Serrano-Wu, M. H., Langley, D. R., Sun, J.-H., O’Boyle II, D. R., et al. (2010) · Nature · doi:10.1038/nature08960 · Cited by 939 · cited 1×
“This approach was used to discover compounds that inhibited hepatitis C virus replication and, after consequent optimization, the approach yielded efficacious clinical candidates with a broad genotype coverag”
MethodA Specific Inhibitor of the Epidermal Growth Factor Receptor Tyrosine Kinase
Fry, D. W., Kraker, A. J., McMichael, A., Ambroso, L. A., Nelson, J. M., Leopold, W. R., Connors, R. W., & Bridges, A. J. (1994) · Science · doi:10.1126/science.8066447 · Cited by 806
Research works printed but not linked: 5
- Landers, P. Human Element: drug industry's big push into technology falls short — testing machines were built to streamline research — but may be stifling it — officials see payoff after 2010. The Wall Street Journal 1 (24 Feb 2004).
- Mullin, R. As high-throughput screening draws fire, researchers leverage science to put automation into perspective. Chem. Eng. News 82, 23–32 (2004).
- HTStec Limited. Cellular Assay Reagents Trends 2009 Report (Cambridge, UK, 2009).
- LaMattina, J. L. (ed.) in Drug Truths: Dispelling the Myths About Pharma R&D 65–66 (John Wiley and Sons, Inc., Hoboken, New Jersey, 2009).
- Inglese, J. in Ask the Expert Forum, ACS Chemical Biology. ACS Publications [online] http://community.acs.org/ChemBiol/AsktheExpert/AsktheExpertArchive/tabid/67/Default.aspx (2008).
Cited by
Items 501–600 of 1,000
DnaG Primase—A Target for the Development of Novel Antibacterial Agents
Ilic, S., Cohen, S., Singh, M., Tam, B., Dayan, A., & Akabayov, B. (2018) · Antibiotics · doi:10.3390/antibiotics7030072 · Cited by 24
Xue, J., Bai, Y., & Liu, H. (2019) · Analytical and Bioanalytical Chemistry · doi:10.1007/s00216-019-01906-y · Cited by 24
Tissue specificity of in vitro drug sensitivity
Yao, F., Tonekaboni, S. A. M., Safikhani, Z., Smirnov, P., El-Hachem, N., Freeman, M., Manem, V. S., & Haibe‐Kains, B. (2017) · Journal of the American Medical Informatics Association · doi:10.1093/jamia/ocx062 · Cited by 24
“lines provide a safe and cost-efficient method by which to measure drug response in multiple cancer types.(8) However, translation of these preclinical findings in animal studies(9,10) and clinical settings(11) is complex, as cancer cell lines may differ from the patient tumors they originate from.”
Park, J., Lee, G.-H., Park, J. Y., Lee, J. C., & Kim, H. C. (2017) · Biofabrication · doi:10.1088/1758-5090/aa9472 · Cited by 26
Alghamdi, M. A. (2025) · Pharmaceuticals · doi:10.3390/ph18071041 · Cited by 26
“These compounds are subsequently optimized via medicinal chemistry and pharmacology for their safety, efficacy, and ADME properties [2,16] (Figure 1).”
Dong, J., Park, S. Y., Nguyen, N. H., Ezhilarasan, R., Martínez-Ledesma, E., Wu, S., Henry, V. K., Piao, Y., Tiao, N., Brunell, D. J., et al. (2018) · Oncotarget · doi:10.18632/oncotarget.24041 · Cited by 23
“The advent of high-throughput screening (HTS) has enabled the screening of large, diverse compound libraries against a panel of cells to validate targets and identify drug candidates for clinical development [6].”
ChemVA: Interactive Visual Analysis of Chemical Compound Similarity in Virtual Screening
Sabando, M. V., Ulbrich, P., Selzer, M. N., Byška, J., Mičan, J., Ponzoni, I., Soto, A. J., Ganuza, M. L., & Kozlíková, B. (2020) · IEEE Transactions on Visualization and Computer Graphics · doi:10.1109/tvcg.2020.3030438 · Cited by 32
“In the last decades, high-throughput screening has been the main procedure applied during the early stages of the drug discovery process [16, 35].”
MethodBozzuto, G., D’Avenio, G., Condello, M., Sennato, S., Battaglione, E., Familiari, G., Molinari, A., & Grigioni, M. (2021) · Journal of Nanobiotechnology · doi:10.1186/s12951-021-01033-w · Cited by 24
Equivariant 3D-Conditional Diffusion Model for De Novo Drug Design
Jia, Z., Yi, H.-C., & You, Z. (2024) · IEEE Journal of Biomedical and Health Informatics · doi:10.1109/jbhi.2024.3491318 · Cited by 24
“High-throughput screening [4] and virtual screening [5] have been successful in assessing large chemical libraries through a variety of filters, which rely on the preparation of rich molecular libraries and enumeration approaches, and can only inefficiently search known and nearby chemical spaces…”
In silicotools used for compound selection during target-based drug discovery and development
Caldwell, G. W. (2015) · Expert Opinion on Drug Discovery · doi:10.1517/17460441.2015.1043885 · Cited by 25
“In addition, most screening decks have a significant distribution of compound concentrations in supposedly single concentration screening decks [82] .”
BackgroundBringing single-molecule spectroscopy to macromolecular protein complexes
Joo, C., Fareh, M., & Kim, V. N. (2012) · Trends in Biochemical Sciences · doi:10.1016/j.tibs.2012.10.005 · Cited by 25
“Although high-throughput screening using libraries of compounds is a proven way to identify novel entities[64], these highly artificial and non-physiological assay systems have low success rates.”
BackgroundMok, N. Y., Maxe, S., & Brenk, R. (2013) · Journal of Chemical Information and Modeling · doi:10.1021/ci300382f · Cited by 23
Generative network complex (GNC) for drug discovery
Grow, C., Gao, K., Nguyen, D. D., & Wei, G. (2019) · Communications in Information and Systems · doi:10.4310/cis.2019.v19.n3.a2 · Cited by 23
“In each LSTM unit, there is a cell consisting of an input gate, an output gate, and a forget gate which are described in the following equations Ht = ot ∗ tanh(Ct), (3)”
BackgroundDocking Finds GPCR Ligands in Dark Chemical Matter
Ballante, F., Rudling, A., Zeifman, A. A., Luttens, A., Vo, D. D., Irwin, J. J., Kihlberg, J. O., Brea, J. M., Loza, M. I., & Carlsson, J. (2019) · Journal of Medicinal Chemistry · doi:10.1021/acs.jmedchem.9b01560 · Cited by 23
Psoralen as an interstrand DNA crosslinker in the selection of DNA-Encoded dynamic chemical library
Zhou, Y., Peng, J., Shen, W., & Li, X. (2020) · Biochemical and Biophysical Research Communications · doi:10.1016/j.bbrc.2020.04.033 · Cited by 23
Cellular Assays with a Molecular Endpoint Measured by SAMDI Mass Spectrometry
Berns, E. J., Cabezas, M. D., & Mrksich, M. (2016) · Small · doi:10.1002/smll.201502940 · Cited by 23
The Importance of Triaging in Determining the Quality of Output from High-Throughput Screening
Jones, P. S., McElroy, S. P., Morrison, A. J., & Pannifer, A. (2015) · Future Medicinal Chemistry · doi:10.4155/fmc.15.121 · Cited by 23
Novel Therapeutic Horizons: SNCA Targeting in Parkinson’s Disease
Caramiello, A. M., & Pirota, V. (2024) · Biomolecules · doi:10.3390/biom14080949 · Cited by 24
Tracking 20 Years of Compound-to-Target Output from Literature and Patents
Southan, C., Varkonyi, P., Boppana, K., Jagarlapudi, S. A. R. P., & Mureşan, S. (2013) · PLoS ONE · doi:10.1371/journal.pone.0077142 · Cited by 25
“The first is that it coincides with technical advances that would have been predicted to sustain or even exceed the acceleration seen between 2000 and 2005 [44].”
BackgroundDiethelm‐Varela, B. (2020) · ChemMedChem · doi:10.1002/cmdc.202000756 · Cited by 22
Computational and data-driven modelling of solid polymer electrolytes
Wang, K., Shi, H., Li, T., Zhao, L., Zhai, H., Korani, D., & Yeo, J. (2023) · Digital Discovery · doi:10.1039/d3dd00078h · Cited by 24
Detection of molecular binding via charge-induced mechanical response of optical fibers
Guan, Y., Shan, X., Wang, S., Zhang, P., & Tao, N. J. (2014) · Chemical Science · doi:10.1039/c4sc01188k · Cited by 22
A rapid and affordable screening platform for membrane protein trafficking
Snyder, J. C., Pack, T. F., Rochelle, L. K., Chakraborty, S. K., Zhang, M., Eaton, A. W., Bai, Y., Ernst, L. A., Barak, L. S., Waggoner, A. S., et al. (2015) · BMC Biology · doi:10.1186/s12915-015-0216-3 · Cited by 24
Concise Review: Cell Surface N-Linked Glycoproteins as Potential Stem Cell Markers and Drug Targets
Boheler, K. R., & Gundry, R. L. (2016) · Stem Cells Translational Medicine · doi:10.5966/sctm.2016-0109 · Cited by 22
Wu, J., Jie, M., Dong, X., Qi, H., & Lin, J. (2016) · Rapid Communications in Mass Spectrometry · doi:10.1002/rcm.7643 · Cited by 22
Molecular-Simulation-Driven Fragment Screening for the Discovery of New CXCL12 Inhibitors
Martinez-Rosell, G., Harvey, M. J., & Fabritiis, G. D. (2018) · Journal of Chemical Information and Modeling · doi:10.1021/acs.jcim.7b00625 · Cited by 25
Yaragorla, S., & Pareek, A. (2018) · Tetrahedron Letters · doi:10.1016/j.tetlet.2018.01.064 · Cited by 22
Sweeney, S., Collins, M., Pandey, R., Chiou, J., Lodi, A., & Tiziani, S. (2020) · Molecular Carcinogenesis · doi:10.1002/mc.23163 · Cited by 23
Girolamo, S. D., Puorger, C., & Lipps, G. (2020) · Microbial Cell Factories · doi:10.1186/s12934-020-01427-9 · Cited by 22
Mazoure, B., Nadon, R., & Makarenkov, V. (2017) · Scientific Reports · doi:10.1038/s41598-017-11940-4 · Cited by 24
“The three main screening technologies represented in ChemBank are high-throughput screening 17 (HTS), high-content screening 18 (HCS) and small-molecule microarrays 16 (SMM).”
BackgroundImmuno-detection by sequencing enables large-scale high-dimensional phenotyping in cells
van Buggenum, J. A. G. L., Gerlach, J. P., Tanis, S. E. J., Hogeweg, M., Jansen, P. W. T. C., Middelwijk, J., van der Steen, R., Vermeulen, M., Stunnenberg, H. G., Albers, C. A., et al. (2018) · Nature Communications · doi:10.1038/s41467-018-04761-0 · Cited by 24
Sako, M., Yasuo, N., & Sekijima, M. (2025) · Journal of Chemical Information and Modeling · doi:10.1021/acs.jcim.4c01385 · Cited by 21
Virtual fragment screening for DNA repair inhibitors in vast chemical space
Luttens, A., Vo, D. D., Scaletti, E. R., Wiita, E., Almlöf, I., Wallner, O. A., Davies, J. R., Košenina, S. P., Meng, L., Long, M., et al. (2025) · Nature Communications · doi:10.1038/s41467-025-56893-9 · Cited by 22
“However, high-throughput screening (HTS) of these libraries often yields low hit rates and weakly active compounds that require extensive optimization 1 .”
Multimodal Precise Control Over Multiselective Carbonylation of 1,3-Enynes
Kuai, C., Wang, Y., Yang, T., & Wu, X. (2025) · Journal of the American Chemical Society · doi:10.1021/jacs.5c00032 · Cited by 21
Daher, A., & de Groot, J. (2017) · Experimental Neurology · doi:10.1016/j.expneurol.2017.09.006 · Cited by 22
“Lastly, the commercial availability of these libraries brings their integrity into question, as quality control standards are not always enforced (Macarron et al., 2011).”
BackgroundTargeting the ubiquitin system by fragment-based drug discovery
Kennedy, C. R., McPhie, K. A., & Rittinger, K. (2022) · Frontiers in Molecular Biosciences · doi:10.3389/fmolb.2022.1019636 · Cited by 21
“Traditional high throughput screening (HTS) methods for drug discovery involve screening libraries of hundreds of thousands of small molecules against a protein of interest or a phenotype (MacArron et al., 2011).”
BackgroundPals, M. J., & Velema, W. A. (2023) · Angewandte Chemie International Edition · doi:10.1002/anie.202302796 · Cited by 21
Alves, V. M., Yasgar, A., Wellnitz, J., Rai, G., Rath, M. K., Braga, R. C., Capuzzi, S. J., Simeonov, A. M., Muratov, E. N., Zakharov, A. V., et al. (2023) · Journal of Medicinal Chemistry · doi:10.1021/acs.jmedchem.3c00482 · Cited by 22
Liu, Y., Zhang, P., Che, C., & Wei, Z. (2024) · Journal of Chemical Information and Modeling · doi:10.1021/acs.jcim.4c00177 · Cited by 26
Application of Fluorescence- and Bioluminescence-Based Biosensors in Cancer Drug Discovery
Kelly, T., & Yang, X. (2024) · Biosensors · doi:10.3390/bios14120570 · Cited by 22
Combined usage of ligand- and structure-based virtual screening in the artificial intelligence era
Dai, J., Zhou, Z., Zhao, Y., Kong, F., Zhai, Z., Zhu, Z., Cai, J., Huang, S., Xu, Y., & Sun, T. (2024) · European Journal of Medicinal Chemistry · doi:10.1016/j.ejmech.2024.117162 · Cited by 24
Applications of CRISPR genome editing technology in drug target identification and validation
Lu, Q., Livi, G. P., Modha, S. S., Yusa, K., Macarrón, R., & Dow, D. J. (2017) · Expert Opinion on Drug Discovery · doi:10.1080/17460441.2017.1317244 · Cited by 28
“Researchers now have access to an unprecedented number of tools, technologies and datasets, with many originally heralded as revolutionary and game changing, including combinatorial chemistry [4], HTS [5], computational methods [6], and RNAi gene knock-down technology [7].”
BackgroundNanoparticle-Based Strategies to Enhance the Efficacy of STING Activators in Cancer Immunotherapy
Qiao, Y., Wei, L., Su, Y., Tan, Q., Yang, X., & Li, S. (2025) · International Journal of Nanomedicine · doi:10.2147/ijn.s515893 · Cited by 21
Schär, S., Raess, L., Malinovska, L., Savickas, S., Cavallo, F., Below, C., Tognetti, M., Shichkova, P., Gourdet, B., Robles, G., et al. (2025) · Analytical Chemistry · doi:10.1021/acs.analchem.5c03829 · Cited by 23
Does Chemistry Have a Future in Therapeutic Innovations?
Meunier, B. (2012) · Angewandte Chemie International Edition · doi:10.1002/anie.201202506 · Cited by 20
A power-free, parallel loading microfluidic reactor array for biochemical screening
Liu, Y., & Li, G. (2018) · Scientific Reports · doi:10.1038/s41598-018-31720-y · Cited by 20
Han, J., Tian, Y., Yu, L., Zhang, Q., Xu, X. J., Zhang, Y., Wang, J., Ma, Z., Bian, J., Luo, C., et al. (2020) · Bioorganic Chemistry · doi:10.1016/j.bioorg.2020.103962 · Cited by 21
Recent progress in fragment-based drug discovery facilitated by NMR spectroscopy
Wang, L., Gao, J., Ma, R., Liu, Y., Liu, M., Zhong, F., Hu, J., Shu-ju, L., Wu, J., Jiang, H., et al. (2021) · Magnetic Resonance Letters · doi:10.1016/j.mrl.2021.100025 · Cited by 20
Advancing small-molecule drug discovery by encoded dual-display technologies
Lessing, A., Petrov, D. D., & Scheuermann, J. (2023) · Trends in Pharmacological Sciences · doi:10.1016/j.tips.2023.08.006 · Cited by 20
Zhu, J., Wang, R., Ma, Z., Zuo, W., & Zhu, M. (2024) · Biomacromolecules · doi:10.1021/acs.biomac.3c01356 · Cited by 20
Arnold, D. M., LaPorte, M. G., Anderson, S. M., & Wipf, P. (2013) · Tetrahedron · doi:10.1016/j.tet.2013.04.127 · Cited by 20
Small-Molecule Library Subset Screening as an Aid for Accelerating Lead Identification
Beresini, M. H., Liu, Y., Dawes, T. D., Clark, K., Orren, L., Schmidt, S., Turincio, R., Jones, S. W., Rodriguez, R. A., Thana, P., et al. (2014) · SLAS DISCOVERY · doi:10.1177/1087057114522515 · Cited by 20
“Compounds in the library fall into three main categories: (1) individual compounds from commercial sources, (2) groups of commercial compounds synthesized around specific chemical scaffolds (these sets number from tens of compounds to more than a thousand compounds), and (3) compounds synthesized for specific therapeu…”
BackgroundOne Size Does Not Fit All: Challenging Some Dogmas and Taboos in Drug Discovery
Chai, C. L. L., & Mátyus, P. (2015) · Future Medicinal Chemistry · doi:10.4155/fmc.15.167 · Cited by 22
High-throughput SRCD using multi-well plates and its applications
Hussain, R., Jávorfí, T., Rudd, T. R., & Siligardi, G. (2016) · Scientific Reports · doi:10.1038/srep38028 · Cited by 20
Li, Y., Wang, X., Ren, J., Lan, X., Li, J., Yi, J., Liu, L., Han, Y., Zhang, S., Li, D., et al. (2017) · BMC Pharmacology and Toxicology · doi:10.1186/s40360-016-0113-6 · Cited by 20
“Regarding assay methods, secreted alkaline phosphatase (SEAP) is extensively used in the detection of positive candidates [16].”
MethodCheminformatics Explorations of Natural Products
Prieto-Martínez, F. D., Norinder, U., & Medina‐Franco, J. L. (2019) · Fortschritte der Chemie Organischer Naturstoffe/Fortschritte der Chemie organischer Naturstoffe/Progress in the chemistry of organic natural products · doi:10.1007/978-3-030-14632-0_1 · Cited by 20
The use of a centrifuge-free RABiT-II system for high-throughput micronucleus analysis
Repin, M., Pampou, S., Brenner, D. J., & Garty, G. Y. (2019) · Journal of Radiation Research · doi:10.1093/jrr/rrz074 · Cited by 20
“On the other hand, universal biotech highthroughput/high content screening (HTS/HCS) robotic systems [13] can switch between several programs, offering a high degree of flexibility for use for different high-throughput biological assays.”
BackgroundBest practices for reporting throughput in biomedical research
Herbig, M., Isozaki, A., Carlo, D. D., Guck, J. R., Nitta, N., Damoiseaux, R. D., Kamikawaji, S., Suyama, E., Shintaku, H., Wu, A. R., et al. (2022) · Nature Methods · doi:10.1038/s41592-022-01483-6 · Cited by 20
Hansson, M., Pemberton, J. S., Engkvist, O., Feierberg, I., Brive, L., Jarvis, P., Balderud, L. Z., & Chen, H. (2013) · SLAS DISCOVERY · doi:10.1177/1087057113499631 · Cited by 20
“The initial results show the following trends: (1) ClogP and molecular size (HEV) are positively correlated with the MHR data, (2) Fsp3 is negatively correlated with the MHR, and (3) f MF is positively correlated with the MHR, but its effect is smaller than those of ClogP, Fsp3, and HEV.”
MethodResultAdvances in natural product discovery: strategies, technologies, and insights
Basnet, B. B., Zhen-yi, Z., Basnet, R., Wei, B., & Wang, H. (2026) · Natural Products and Bioprospecting · doi:10.1007/s13659-025-00556-1 · Cited by 23
“…and combinatorial synthesis intensively exploited between the 1980s to early 2000s improved the lead discovery by increasing the hit rate to approximately 10–40% [15], but these systems have their own set of restrictions, such as limited chemical diversity and screening library chemspace size [16].”
Diao, X., Zhang, H., Wang, S., Wang, Z., & Zhang, Q. (2026) · Frontiers in Pharmacology · doi:10.3389/fphar.2026.1748478 · Cited by 23
Structure–activity relationships and drug design
Gianti, E., & Zauhar, R. J. (2020) · Elsevier eBooks · doi:10.1016/b978-0-12-820007-0.00007-6 · Cited by 19
Gerardo‐Nava, J., Jansen, J., Günther, D., Klasen, L., Thiebes, A. L., Nießing, B., Bergerbit, C., Meyer, A. A., Linkhorst, J., Barth, M., et al. (2023) · Advanced Healthcare Materials · doi:10.1002/adhm.202301030 · Cited by 20
Deep learning assisted high throughput screening of ionic liquid electrolytes for NRR and CO2RR
Song, Y., Guo, Y., Chen, J., Yuan, M., & Dong, K. (2023) · Journal of environmental chemical engineering · doi:10.1016/j.jece.2023.110556 · Cited by 19
DeCoST: A New Approach in Drug Repurposing From Control System Theory
Nguyen, T. M., Muhammad, S. A., Ibrahim‐Shaikh, S., Ma, L., Guo, J., Bai, B., & Zeng, B. (2018) · Frontiers in Pharmacology · doi:10.3389/fphar.2018.00583 · Cited by 20
“Integration of other resources, such as drugs, genes, and systems associated with side-effects (Kuhn et al., 2016; Maier et al., 2018) and high-throughput screening (Deftereos et al., 2011; Macarron et al., 2011) would also be valuable expansions of this work in the future.”
BackgroundApplications of Computers in Pharmaceutical Product Formulation
Deb, P. K., Al-Attraqchi, O. H. A., Al-Qattan, M. N. M., Mailavaram, R. P., & Tekade, R. K. (2018) · Elsevier eBooks · doi:10.1016/b978-0-12-814421-3.00019-1 · Cited by 22
Singh, N., Chaput, L., & Villoutreix, B. O. (2020) · Journal of Chemical Information and Modeling · doi:10.1021/acs.jcim.0c00545 · Cited by 19
Pal, R., Dai, M., & Seleem, M. N. (2021) · Scientific Reports · doi:10.1038/s41598-021-90314-3 · Cited by 19
A High Throughput Approach for Designing Polymers That Mimic the TRAIL Protein
Li, Z., Han, Z., Stenzel, M. H., & Chapman, R. (2022) · Nano Letters · doi:10.1021/acs.nanolett.1c04469 · Cited by 19
Thermodynamic Proxies to Compensate for Biases in Drug Discovery Methods
Ekins, S., Litterman, N. K., Lipinski, C. A., & Bunin, B. A. (2015) · Pharmaceutical Research · doi:10.1007/s11095-015-1779-y · Cited by 19
Advances in discovering small molecules to probe protein function in a systems context
Doyle, S. K., Pop, M. S., Evans, H. L., & Koehler, A. N. (2015) · Current Opinion in Chemical Biology · doi:10.1016/j.cbpa.2015.10.032 · Cited by 22
Zhang, B., Fu, Y., Huang, C., Zheng, C., Wu, Z., Zhang, W., Yang, X., Gong, F., Li, Y., Chen, X., et al. (2016) · Scientific Reports · doi:10.1038/srep21872 · Cited by 20
“Specially, the threshold fits to an extreme value distribution, which forms the basis of a blast algorithm and sequence similarity (4) Choose the Scut, such that the histogram best fits an EVD based on goodness of fit.”
BackgroundKovács, Z., Szarka, M., Szigeti, M., & Guttman, A. (2016) · Journal of Pharmaceutical and Biomedical Analysis · doi:10.1016/j.jpba.2016.06.002 · Cited by 19
Have microfluidics delivered for drug discovery?
Chandrasekaran, A., Abduljawad, M. M., & Moraes, C. (2016) · Expert Opinion on Drug Discovery · doi:10.1080/17460441.2016.1193485 · Cited by 19
“Cell-based high-throughput screening (HTS) techniques have enabled researchers to screen over a million compounds in 1–3 months [2], but only 1 in every 5000 promising ‘hits’ successfully transitions from the benchtop to the market [3], as the vast majority of discoveries fail during animal testing and human clinical…”
BackgroundAdvances in relaxation and memory effects of magnetic nanoparticles for biomedical applications
Singh, P., Shankhwar, N., Nachnani, A., Singh, P. K., Kumar, U., Singh, S., & Upadhyay, C. (2025) · Progress in Materials Science · doi:10.1016/j.pmatsci.2025.101521 · Cited by 22
de Wouters, T., Ledue, F., Nepelska, M., Dore, J. M., Blottière, H. M., & Lapaque, N. (2014) · PLoS ONE · doi:10.1371/journal.pone.0105598 · Cited by 18
“This can only be achieved in qualitatively exploitable way by a high degree of automatisation and adapted analysis techniques as used in high throughput screening for drug-discovery [17].”
MethodMultifocal hyperspectral Raman imaging setup for multi-well plates
Wolf, S., Popp, J., & Frosch, T. (2022) · Sensors and Actuators B Chemical · doi:10.1016/j.snb.2022.132949 · Cited by 18
Zhou, Y., & Reynolds, T. B. (2024) · Journal of Fungi · doi:10.3390/jof10030171 · Cited by 19
“High-throughput screening (HTS) and rational drug design are two ways to identify leads for drug development [11,12].”
BackgroundDual-view jointly learning improves personalized drug synergy prediction
Li, X., Shen, B., Feng, F., Li, K., Tang, Z., Ma, L., & Li, H. (2024) · Bioinformatics · doi:10.1093/bioinformatics/btae604 · Cited by 22
“However, exhaustive searching of the entire combination space is impossible due to high costs and time consumption for the exponential increase of potential combinations (Macarron et al. 2011, Goswami et al. 2015).”
Hit Expansion Approaches Using Multiple Similarity Methods and Virtualized Query Structures
Bergner, A., & Parel, S. P. (2013) · Journal of Chemical Information and Modeling · doi:10.1021/ci400059p · Cited by 18
Innovation in academic chemical screening: filling the gaps in chemical biology
Hasson, S. A., & Inglese, J. (2013) · Current Opinion in Chemical Biology · doi:10.1016/j.cbpa.2013.04.018 · Cited by 18
“com reinforce the technique’s power [1] and tribulations [2,3].”
MethodScaiano, J. C., & Lanterna, A. E. (2017) · The Journal of Organic Chemistry · doi:10.1021/acs.joc.6b03010 · Cited by 18
Discovery of novel CBP bromodomain inhibitors through TR-FRET-based high-throughput screening
Zhang, F., Sun, Z., Liao, L., Zuo, Y., Zhang, D., Wang, J., Chen, Y., Xiao, S.-H., Jiang, H., Lu, T., et al. (2019) · Acta Pharmacologica Sinica · doi:10.1038/s41401-019-0256-2 · Cited by 18
Blincoe, W. D., Lin, S., Dreher, S. D., & Sheng, H. (2020) · Tetrahedron · doi:10.1016/j.tet.2020.131434 · Cited by 19
Employing Photocatalysis for the Design and Preparation of DNA‐Encoded Libraries: A Case Study
Kölmel, D. K., Zhu, H., Flanagan, M. E., Sakata, S. K. L., Harris, A. R., Wan, J., & Morgan, B. A. (2021) · The Chemical Record · doi:10.1002/tcr.202000148 · Cited by 18
Grisard, E., Névo, N., Lescure, A., Doll, S. G., Corbé, M., Jouve, M. J., Lavieu, G., Joliot, A., Nery, E. D., Jaular, L. M., et al. (2022) · Journal of Extracellular Vesicles · doi:10.1002/jev2.12242 · Cited by 18
“HCS methods are extensively used to rapidly identify small molecules with potential biological functions, and are of special interest for repurposing drug applications when performed using chemical libraries compounds already approved by regulatory agencies (FDA, EMA …) (Macarron et al., 2011).”
Probabilistic Substructure Mining From Small‐Molecule Screens
Ranu, S., Calhoun, B. T., Singh, A. K., & Swamidass, S. J. (2011) · Molecular Informatics · doi:10.1002/minf.201100058 · Cited by 18
Fallarero, A., Hanski, L. L., & Vuorela, P. M. (2014) · Planta Medica · doi:10.1055/s-0034-1383061 · Cited by 22
“…of the assay relates to the stability of the response that is offered by the assay, to ensure that similarly trustable results are obtained when the assay is performed in different wells, plates, days, and by different human operators or using different types of laboratory equipment [13].”
BackgroundThyparambil, A. A., Bazin, I., & Guiseppi‐Elie, A. (2017) · Toxins · doi:10.3390/toxins9120395 · Cited by 20
“According to some estimates, high-throughput screening could currently screen up to 100,000 compounds a day, using extremely tiny volumes of reactants, at a low cost per molecule screened [52].”
BackgroundExploring Activity Profiles of PAINS and Their Structural Context in Target–Ligand Complexes
Siramshetty, V. B., Preißner, R., & Gohlke, B.-O. (2018) · Journal of Chemical Information and Modeling · doi:10.1021/acs.jcim.8b00385 · Cited by 19
Nelson, J., Simpkins, S. W., Safizadeh, H., Li, S. C., Piotrowski, J. S., Hirano, H., Yashiroda, Y., Osada, H., Yoshida, M., Boone, C. M., et al. (2017) · Bioinformatics · doi:10.1093/bioinformatics/btx732 · Cited by 18
GenSMILES: An enhanced validity conscious representation for inverse design of molecules
Bhadwal, A. S., Kumar, K., & Kumar, N. (2023) · Knowledge-Based Systems · doi:10.1016/j.knosys.2023.110429 · Cited by 17
Performance of Dark Chemical Matter in High Throughput Screening
Muegge, I., & Mukherjee, P. K. (2016) · Journal of Medicinal Chemistry · doi:10.1021/acs.jmedchem.6b01038 · Cited by 17
Veríssimo, G. C., Serafim, M. S. M., Kronenberger, T., Ferreira, R. S., Honório, K. M., & Maltarollo, V. G. (2022) · Expert Opinion on Drug Discovery · doi:10.1080/17460441.2022.2114451 · Cited by 18
“Once again, there are several drugs on the market as a result of HTS campaigns, such as sitagliptin, gefitinib, tipranavir, and others [10].”
BackgroundLi, J.-N., Yang, G. C., Zhao, P., Wei, X.-X., & Shi, J. (2023) · Bioinformatics · doi:10.1093/bioinformatics/btad222 · Cited by 23
Virtual Screening Process: A Guide in Modern Drug Designing
Panwar, U., Aarthy, M., Khan, M. A., Selvaraj, C., & Singh, S. K. (2023) · Methods in molecular biology · doi:10.1007/978-1-0716-3441-7_2 · Cited by 17
Grasela, T. H., & Slusser, R. (2014) · Clinical Pharmacology & Therapeutics · doi:10.1038/clpt.2013.242 · Cited by 17
Latent Hit Series Hidden in High-Throughput Screening Data
Varin, T. V., Didiot, M.-C., Parker, C. N., & Schuffenhauer, A. (2011) · Journal of Medicinal Chemistry · doi:10.1021/jm201328e · Cited by 17
VSPrep: A KNIME Workflow for the Preparation of Molecular Databases for Virtual Screening
Gally, J., Bourg, S., Fogha, J., Do, Q., Aci‐Sèche, S., & Bonnet, P. (2019) · Current Medicinal Chemistry · doi:10.2174/0929867326666190614160451 · Cited by 17
Baum, K., Schuchhardt, J., Wolf, J., & Busse, D. (2019) · Cell Systems · doi:10.1016/j.cels.2019.07.009 · Cited by 19
“Population-based high-throughput data are the basis of many recent innovations in biomedical and pharmaceutical research (Macarron et al., 2011).”
Background
Metadata
- Authors
- Macarron, R., Banks, M. N., Bojanic, D., Burns, D. J., Cirovic, D. A., Garyantes, T., Green, D. V. S., Hertzberg, R. P., Janzen, W. P., Paslay, J. W., Schopfer, U., & Sittampalam, G. S.
- Affiliations
- Bristol-Myers Squibb (United States) (US)
- Novartis (United States) (US)
- Abbott (United States) (US)
- Sanofi (France) (FR)
- GlaxoSmithKline (United Kingdom) (GB)
- GlaxoSmithKline (United States) (US)
- University of North Carolina at Chapel Hill (US)
- The University of Kansas Cancer Center (US)
- Novartis (Switzerland) (CH)
- Pfizer (United States) (US)
- Venue
- Nature Reviews Drug Discovery
- Published
- 2011-03
- Volume
- 10
- Issue
- 3
- Pages
- 188-195
- ISSN
- 1474-1776 (ISSN-L)
- 1474-1784
- OpenAlex
- W2031441006
- Cited by
- 1,364
- References
- 65
- Citations by year
- 2026: 113 · 2025: 117 · 2024: 99 · 2023: 103 · 2022: 82 · 2021: 107 · 2020: 106 · 2019: 77 · 2018: 105 · 2017: 87 · 2016: 96 · 2015: 64 · 2014: 61 · 2013: 73 · 2012: 54
- FWCI
- 6.80
- Type
- journal article
- Language
- en
- Open access
- closed
- Licence
- www.springer.com/tdm (tdm)
- Locations
- Nature Reviews Drug Discovery (publishedVersion)
- PubMed (publishedVersion)
- Topics
- Life Sciences › Pharmacology, Toxicology and Pharmaceutics › Drug Discovery › Computational Drug Discovery Methods
- Social Sciences › Economics, Econometrics and Finance › Economics and Econometrics › Pharmaceutical Economics and Policy
- Physical Sciences › Chemistry › Organic Chemistry › Chemical Synthesis and Analysis
- Keywords
- high-throughput screening, drug discovery, chemical biology
- MeSH terms
- Animals, Drug Evaluation, Preclinical, Humans, Drug Design, Biomedical Research, Small Molecule Libraries
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.